High dose intravenous streptokinase in acute myocardial infarction

Neuhaus, Karl-Ludwig; Tebbe, Ulrich; Sauer, G.; Kreuzer, H; Köstering, H.

doi:10.1002/clc.4960060903

Cited by 67 publications

(20 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The patient population consisted of 101 consecutive patients who were entered into a prospective study of intravenous streptokinase in acute myocardial infarction and in whom ie systemic blood pressure was continuously monitored duri the infusion of streptokinase. The study inclusion criteria were (1) chest pain of 3 hr or less duration, (2) ST segment elevation indicative of transmural ischemia, (3) unresponsiveness of both the chest pain and the electrocardiographic changes to sublingual nitroglycerin, (4) no contraindication to thrombolytic or anticoagulant therapy, and (5) consent of both the patient and his or her physician. The diagnosis of acute myocardial infarction was subsequently confirmed by a rise in serum levels of the creatine kinase MB isoenzyme in all patients.…”

Section: Methodsmentioning

confidence: 99%

“…[1][2][3][4][5][6][7][8][9] In most recent studies, intravenous streptokinase has been administered rapidly so as to achieve a high concentration of streptokinase in proximity to the coronary thrombus and thereby accelerate thrombolysis. '0- '3 One limitation of the administration of a rapid intravenous infusion of streptokinase is that it can cause a significant fall in systemic blood pressure.4' 5' This study investigates the frequency and severity of the hypotensive effect of intravenous infusion of streptokinase in patients with acute myocardial infarction and its relationship to the rate of the infusion.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The hypotensive effect of intravenous streptokinase in patients with acute myocardial infarction.

Lew¹,

Laramee

Cercek³

et al. 1985

Circulation

View full text Add to dashboard Cite

We studied the hypotensive effect of a rapid intravenous infusion of high-dose streptokinase in 98 patients with an acute myocardial infarction. The systolic blood pressure fell from 132 + 20 (range 90 to 174) to 97 21 mm Hg (range 58 to 152) at 15 8 min (range 4 to 40) after the commencement of the streptokinase infusion (p < .00 1). A fall in diastolic blood pressure from 80 + 16 (range 51 to 105) to 61 15 mm Hg (range 32 to 92) accompanied the fall in systolic pressure (p < .001). The fall in blood pressure was associated with an increase in heart rate (73 14 to 78 + 17 beats/min, p < .001), preceded the appearance of clinical signs of reperfusion by 37 38 min and was similar in magnitude and timing in patients with anterior and inferior infarction. There were direct relationships between the rate of infusion of streptokinase and both the magnitude (r = .49, p < .001) and the rate of fall of systolic blood pressure (r = .67, p < .001) as well as both the magnitude and rate of fall of diastolic blood pressure. In most patients, the fall in blood pressure was transient (9 + 6 min, range = 2 to 30) and easily managed by slowing or stopping the infusion, placing the patient in the Trendelenburg position, or by administering an infusion of low-dose norepinephrine or dopamine. However, in four patients with severe left ventricular dysfunction, severe hypotension persisted for more than 60 min. Our data indicate that in patients with either anterior or inferior myocardial infarction, a rapid infusion of high-dose intravenous streptokinase may frequently cause transient and sometimes severe hypotension, the magnitude of which is directly related to the rate of infusion of streptokinase. Circulation 72, No. 6, 1321No. 6, -1326No. 6, , 1985 SHORT-TERM INTRAVENOUS INFUSION of high-dose streptokinase is an effective method of coronary thrombolysis and coronary artery reperfusion during an acute myocardial infarction.1-9 In most recent studies, intravenous streptokinase has been administered rapidly so as to achieve a high concentration of streptokinase in proximity to the coronary thrombus and thereby accelerate thrombolysis.'0-'3 One limitation of the administration of a rapid intravenous infusion of streptokinase is that it can cause a significant fall in systemic blood pressure.4' 5' This study investigates the frequency and severity of the hypotensive effect of intravenous infusion of streptokinase in patients with acute myocardial infarction and its relationship to the rate of the infusion. MethodsPatient population. The patient population consisted of 101 consecutive patients who were entered into a prospective study of intravenous streptokinase in acute myocardial infarction and in whom ie systemic blood pressure was continuously monitored duri the infusion of streptokinase. The study inclusion criteria were (1) chest pain of 3 hr or less duration, (2) ST segment elevation indicative of transmural ischemia, (3) unresponsiveness of both the chest pain and the electrocardiographic changes to sublingual n...

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

The hypotensive effect of intravenous streptokinase in patients with acute myocardial infarction.

Lew¹,

Laramee

Cercek³

et al. 1985

Circulation

View full text Add to dashboard Cite

show abstract

“…Intravenous heparin was continued for 8-14 days at a rate adjusted to maintain the activated partial thromboplastin time at 1 1/2-2 times control. At 24 hours after angiography, heparin was discontinued for [2][3][4] hours to allow removal of the sheaths, and it was then reinstituted with a bolus of 2,000-5,000 units. For at least 24 …”

Section: Patients and Methods Patient Selection Criteriamentioning

confidence: 99%

“…[1][2][3][4][5][6] Recombinant tissue-type plasminogen activator (rt-PA) has been shown to be a more effective thrombolytic agent than streptokinase7-9 and to produce less extensive systemic fibrinogenolysis. '0 In multicenter trials, intravenous rt-PA has been associated with coronary reocclusion rates of 10% to 30% despite heparin anticoagulation.…”

mentioning

confidence: 99%

Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.

et al. 1988

View full text Add to dashboard Cite

Sixty-eight patients with acute "transmural" myocardial infarction presenting within 6 hours (range, 1.3-5.8 hours) of onset of chest pain were given intravenous recombinant tissue-type plasminogen activator (rt-PA) at a dosage of 1 mg/kg during 90 minutes. Coronary angiography at 90 minutes revealed a patent infarct-related coronary artery in 52 patients (76%). These patients were randomized either to treatment by continuous infusion of heparin alone (27 patients) or to treatment by heparin and a maintenance infusion of rt-PA at a dosage of 0.8 mg/kg during 4 hours (25 patients). Coronary angiography was repeated 60 minutes after the start of the maintenance infusion and again after 8-14 days. Acute symptomatic reocclusion of the infarct-related artery occurred during the 1-hour observation period in five (19%) patients treated with heparin alone but in none of the patients treated with rt-PA (p = 0.05). The measured residual stenosis of the patent infarct-related coronary artery was similar in the heparin-treated and the rt-PA-treated groups at 90 minutes infusion: 66±14% versus 68±13% diameter stenosis, respectively (mean ± SD) and 1.1 ± 1.1 mm2 versus 0.82 ± 0.7 mm2 area (p = 0.35). At 8-14 days after infusion, residual stenosis was unchanged in the heparin-treated group, but it improved to 55 ± 17% (p = 0.001) and 1.6 ± 1.2 mm2 (p = 0.003) in the rt-PA-treated group. At 90 minutes of infusion, residual intraluminal thrombus was observed in 29 of the 52 patients (56%) with a comparably measured distribution in the two groups (p= 0.43). At 150 minutes, however, the extent of intraluminal thrombus was significantly reduced in the rt-PA-treated group as compared with the heparin-treated group (p= 0.03). In-hospital ischemic events (symptomatic reocclusion, unstable angina, or cardiovascular death) occurred in 12 patients of the heparin-treated group but only in three patients of the rt-PA-treated group (p = 0.03). Fibrinogen levels decreased to 65 ± 21% of baseline at 90 minutes of rt-PA infusion. During the rt-PA maintenance infusion, fibrinogen fell slightly from 63 ± 26 to 57 ± 28% (p = 0.18). This study shows that after successful reperfusion with 1 mg/kg rt-PA during 90 minutes, a maintenance infusion of 0.8 mglkg rt-PA during 4 hours prevents acute symptomatic coronary artery reocclusion, and it reduces the frequency of ischemic events and the severity of residual coronary artery stenosis at hospital discharge. (Circulaton 1988;78:546-556) S uccessful thrombolytic therapy of acute myoin-hospital reocclusion rate after reperfusion with cardial infarction does not always produce intravenous streptokinase has ranged from 10% to stable coronary artery patency. The reported

show abstract

“…Throughout the entire period of observation in the catheterization laboratory, no resolution of the thrombus was noted, and the vessel remained 90% stenotic. At follow-up angiography 12 6. Change in caliber of infarct-related artery at follow-up.…”

mentioning

confidence: 99%

Prospective randomized trial of intravenous and intracoronary streptokinase in acute myocardial infarction.

Rogers¹,

Mantle²,

Hood³

et al. 1983

Circulation

171

View full text Add to dashboard Cite

To evaluate the relative thrombolytic efficacy and complications of intracoronary vs high-dose, short-term intravenous streptokinase infusion in patients with acute myocardial infarction, we performed baseline coronary arteriography and then randomly allocated 51 patients with acute myocardial infarction to receive either intracoronary (n = 25) or intravenous (n = 26) streptokinase. Patients getting the drug by the intracoronary route received 240,000 IU of streptokinase into the infarct-related artery over 1 hr, whereas those getting the drug by the intravenous route received either 500,000 IU of streptokinase over 15 min (n = 10) or I million IU of streptokinase over 45 min (n = 16). Angiographically observed thrombolysis occurred in 76% (19/25) of the patients receiving intracoronary streptokinase, in 10% (1/10) of the patients receiving 500,000 IU of streptokinase intravenously, and in 44% (7/16) of the patients receiving 1 million IU of streptokinase intravenously. Among patients in whom thrombolysis was observed, mean elapsed time from onset of streptokinase infusion until lysis was 31 ± 18 min in patients receiving intracoronary streptokinase and 38 + 20 min in those receiving intravenous streptokinase (p = NS). Among patients in whom intravenous streptokinase "failed," intracoronary streptokinase in combination with intracoronary guidewire manipulation recanalized only 7% (1/15). Fibrinogen levels within 6 hr after streptokinase were significantly lower in the patients receiving intravenous streptokinase (39 ± 17 mg/dl) than the levels in those receiving intracoronary streptokinase (88 + 70 mg/dl) (p < .05) but were similar 24 hr after streptokinase in the two groups. Bleeding requiring transfusion occurred in one patient in each group. Thus, in this prospective randomized trial of intracoronary vs intravenous streptokinase, hemorrhagic complications were few, although both regimens produced a systemic lytic state. Although the thrombolytic efficacy of intracoronary streptokinase was superior to that of high-dose, short-term intravenous streptokinase, the higher-dose intravenous regimen (1 million IU over 45 min) achieved thrombolysis in a significant minority (44%) of patients and might be useful therapy for patients not having access to emergency catheterization.Circulation 68, No. 5, 1051No. 5, -1061No. 5, , 1983 RECENTLY, intracoronary streptokinase has achieved considerable popularity as a means for recanalizing acutely thrombosed coronary arteries in patients with evolving acute myocardial infarction. 1 Unfortunately, emergency coronary arteriography and intracoronary streptokinase infusion require sophisticated equipment and a specially trained operator and

show abstract

High dose intravenous streptokinase in acute myocardial infarction

Cited by 67 publications

References 12 publications

The hypotensive effect of intravenous streptokinase in patients with acute myocardial infarction.

The hypotensive effect of intravenous streptokinase in patients with acute myocardial infarction.

Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.

Prospective randomized trial of intravenous and intracoronary streptokinase in acute myocardial infarction.

Contact Info

Product

Resources

About